Connect Biopharma is trading 6.4% up at $2.51, with the move appearing mainly sector-driven as biotech stocks gain broadly.
- No new company-specific announcement was identified for September 2, 2026.
- Investors may also be positioning ahead of expected September topline results from the Phase 2 Seabreeze STAT asthma and COPD studies.
- Enrollment is complete in both trials, with asthma data expected in early September.